"For years, the discussion around cannabis revolved almost exclusively around THC and CBD. THC has long been recognized for its psychoactive properties, while CBD gained widespread popularity for its non-intoxicating profile and mainstream wellness appeal. Yet as scientific research progresses and the cannabis industry matures, a broader picture of the plant's complexity is coming into focus. Within the trichomes of each flower lies a diverse set of cannabinoids-over a hundred distinct compounds, many of which remain understudied and underappreciated."
"Among these lesser-known players, three minor cannabinoids-CBG (cannabigerol), CBC (cannabichromene), and THCV (tetrahydrocannabivarin)-are steadily capturing the attention of researchers, cultivators, and consumers alike. While present in smaller amounts compared to THC and CBD, these cannabinoids demonstrate unique effects that may hold significant potential for wellness, consumer experience, and the evolution of the cannabis marketplace. This article explores why these compounds matter, what makes them distinct, and how they could influence the way consumers, brands, and medical professionals think about cannabis in the future."
"Minor cannabinoids are naturally occurring compounds in cannabis that exist in smaller concentrations than THC and CBD. Though "minor" in abundance, their potential effects are anything but negligible. Many interact with the body's endocannabinoid system (ECS) in ways that differ from THC or CBD, opening possibilities for targeted effects and therapeutic applications. Advancements in extraction technology, selective breeding, and genetic research are allowing cultivators to produce cannabis chemotypes rich in specific minor cannabinoids."
THC and CBD dominated cannabis conversations, but cannabis flowers contain over a hundred distinct cannabinoids within trichomes, many understudied. Minor cannabinoids like CBG, CBC, and THCV occur in smaller concentrations yet interact with the endocannabinoid system differently from THC and CBD, suggesting possibilities for targeted effects and therapeutic uses. Advances in extraction, selective breeding, and genetic research enable cultivators to produce chemotypes rich in specific minor cannabinoids. Consumer demand for experiences beyond THC-driven highs is rising, driving interest from researchers, cultivators, and medical professionals and opening new product and market opportunities.
Read at stupidDOPE | Est. 2008
Unable to calculate read time
Collection
[
|
...
]